Ariel Investments, LLC — Ariel Small/Mid Cap Value Composite on Charles River Laboratories International, Inc.
Thesis
Charles River benefited from better biopharmaceutical and biotech customer demand and stronger Discovery & Safety Assessment bookings. Funding conditions for research showed early signs of stabilization. Portfolio optimization and automation lifted profitability while buybacks continued without undermining balance-sheet strength. Ariel expects renewed biopharma R&D investment to underpin sustained growth and earnings expansion.
“We believe CRL will continue to benefit from a recovery in biopharmaceutical R&D spending”
Key risks
- Research funding markets may fail to stabilize, delaying a recovery in biopharma R&D spending.
- Bookings and demand from biotechnology customers could remain uneven after the initial improvement.